Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
about
The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.Development of Companion DiagnosticsBCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.Molecular imaging agents: impact on diagnosis and therapeutics in oncologyA functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin.Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell linesPhase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PETDifferential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer."Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice.Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistanceOvercoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Site-specific metabolic phenotypes in metastatic breast cancer.Comparison of hormone receptor status in primary and recurrent breast cancer.Receptor conversion in distant breast cancer metastasesComparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor lossEndocrine-responsive breast cancer and strategies for combating resistance.Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planningInhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines.Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer studyExpression of Lipid Metabolism-Related Proteins in Metastatic Breast CancerEstrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancerDeregulation of NR2E3, an orphan nuclear receptor, by benzo(a)pyrene-induced oxidative stress is associated with histone modification status change of the estrogen receptor gene promoter.The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistancePharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinasep53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells.Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.
P2860
Q24796156-935EA7A6-9FF4-4D4C-88AA-B575ADCE5571Q25257858-0D23D6BC-2B26-4F2D-B156-B17868CECC99Q26774670-CC304C13-1C9D-4FB6-AC90-F3000453D8B3Q30432099-C18C3D8C-9440-4C8D-BEE8-C71380464E6AQ30433423-449AFC69-C0F8-43F8-B96B-122DE0CF21C6Q30999913-9909BD2B-4B60-4392-8029-402F2639B492Q31031200-C9EED6B7-59F2-479C-B382-0B4D08E6CC5EQ33403066-ADF6B420-ADFE-40BF-B6A1-DC46E95B38D9Q33429255-7C1F7B8F-9702-422F-8725-E3A83C405A14Q33699614-6BBE333E-13AB-462B-80B9-77F7D5C03A63Q33793142-4A869B7D-6047-4005-BB39-D11897B3DA6DQ33939772-9695AA95-A3A0-4F97-ADC9-FEF7AEF10E2CQ34235986-912C35E8-6040-4A0D-BD90-A86EE106FEF2Q34332592-D6D20A96-46D4-4D6B-AA15-A6DA55565F9DQ34369138-7B7A414B-5927-4874-B583-D54EA8F8CA4BQ34374852-0F3336D4-1970-4A0C-BDE6-E295EB626A26Q34508653-C8AE0099-347B-45EA-9FA5-EE20064DE66AQ34613506-CDDC1674-E6E4-471E-9966-CD1E89881419Q34650211-CE5F5A66-C5FB-4624-AE59-D17029121A1DQ34657786-4527EB45-A557-4D68-AF61-F2E937C8AC23Q34788659-36C8AB04-04D1-43B4-A3D2-A63489086146Q34987082-6BFB7007-35D8-42E6-AAB8-45707AD10ED7Q34989060-B62EDF14-2F6D-4F54-91B0-74EA7D84A5CFQ35082619-193E92B4-A98A-467D-A7FF-19CB9179BFE9Q35084786-B66D896A-6380-4296-8FA3-7D1C117ED0DFQ35090896-173870C7-C686-4975-B45F-616EB2BF73F2Q35668687-E08B2E3E-FEE7-4109-BD66-F970796005EEQ35690804-5F332E7E-E7A5-40B5-90B3-0F6445A6AB78Q35763076-1C6CADEA-5BF0-4FC6-B447-8A56520983FFQ35793341-D1652A6B-9A67-4B5F-9D5A-C6FA4363521DQ35914666-D259BE40-0A95-4335-9CA5-77AD7142BC74Q36013029-527BAC40-2FCA-43FD-96D6-7192CAE6EC4AQ36135818-51E0D033-48F6-4F66-B0ED-40BDF16C36F5Q36216301-5BB6ED80-B0A6-4196-8370-F86D990D171FQ36236032-E4BAE599-BDBA-4528-9279-F948BD2B1BC3Q36293034-6A8C4B60-190E-40F2-8DFC-AC6854307C83Q36294864-90C32AD8-E3B4-4029-BACC-F8235BE0CA2FQ36344573-36743C0C-956F-4E5F-94D6-9BC7640DDDDDQ36452355-E9B9D97C-C5F7-43BF-ADB3-41D6DBA513BFQ36617556-7E597DF3-BD3A-4DD1-A54D-3DC92841ADA5
P2860
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Loss of estrogen receptor in r ...... response to endocrine therapy.
@ast
Loss of estrogen receptor in r ...... response to endocrine therapy.
@en
Loss of estrogen receptor in r ...... response to endocrine therapy.
@nl
type
label
Loss of estrogen receptor in r ...... response to endocrine therapy.
@ast
Loss of estrogen receptor in r ...... response to endocrine therapy.
@en
Loss of estrogen receptor in r ...... response to endocrine therapy.
@nl
prefLabel
Loss of estrogen receptor in r ...... response to endocrine therapy.
@ast
Loss of estrogen receptor in r ...... response to endocrine therapy.
@en
Loss of estrogen receptor in r ...... response to endocrine therapy.
@nl
P2093
P1476
Loss of estrogen receptor in r ...... response to endocrine therapy.
@en
P2093
P304
P356
10.1200/JCO.1996.14.9.2584
P407
P577
1996-09-01T00:00:00Z